资产负债表（Adamis Pharmaceuticals Corp）
| 2023年中报 | 2023年一季报 | 2022年年报 | 2022年三季报 | 2022年中报 | 2022年一季报 | |
|---|---|---|---|---|---|---|
| 截止日期 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 |
| 报表类型 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 |
| 报表年结日 | 1231 | 1231 | 1231 | 1231 | 1231 | 1231 |
| 原始币种 | 美元 | 美元 | 美元 | 美元 | 美元 | 美元 |
| 上市前/上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 |
| 流动资产： | ||||||
| 现金及现金等价物(元) | 640,254.00 | 3,099,843.00 | 1,081,364.00 | 2,419,960.00 | 8,875,925.00 | 17,767,735.00 |
| 受限制存款及现金流动(元) | 30,090.00 | 30,079.00 | 30,068.00 | 30,056.00 | 30,045.00 | 30,034.00 |
| 应收账款及票据(元) | 18,971.00 | 21,173.00 | 1,085,009.00 | 1,554,015.00 | - | 1,516,149.00 |
| 预付款项及其他应收款流动(元) | 658,119.00 | 750,272.00 | 1,884,015.00 | 803,415.00 | 1,751,905.00 | 4,167,357.00 |
| 存货(元) | 664,358.00 | 664,358.00 | 1,238,778.00 | 1,092,445.00 | 440,198.00 | 31,998.00 |
| 流动资产其他项目(元) | 1,438,906.00 | 2,981,305.00 | 3,952,916.00 | 4,188,239.00 | 4,222,542.00 | 4,277,153.00 |
| 流动资产合计(元) | 3,450,698.00 | 7,547,030.00 | 9,272,150.00 | 10,088,130.00 | 15,320,615.00 | 27,790,426.00 |
| 非流动资产： | ||||||
| 物业、厂房及设备(元) | 1,142,869.00 | 1,244,669.00 | 1,288,894.00 | 1,594,856.00 | 1,835,885.00 | 2,137,895.00 |
| 非流动资产其他项目(元) | 155,583.00 | 284,396.00 | 369,796.00 | 454,300.00 | 537,935.00 | 620,711.00 |
| 非流动资产合计(元) | 1,298,452.00 | 1,529,065.00 | 1,658,690.00 | 2,049,156.00 | 2,373,820.00 | 2,758,606.00 |
| 总资产(元) | 4,749,150.00 | 9,076,095.00 | 10,930,840.00 | 12,137,286.00 | 17,694,435.00 | 30,549,032.00 |
| 流动负债： | ||||||
| 融资租赁负债流动(元) | 157,246.00 | 250,361.00 | 342,562.00 | 368,809.00 | - | - |
| 应付账款及票据(元) | 11,365,931.00 | 9,780,979.00 | 7,937,493.00 | 5,297,717.00 | 4,516,722.00 | 4,891,462.00 |
| 其他应付款及应计费用(元) | 2,200,716.00 | 1,829,554.00 | 1,510,053.00 | 1,341,759.00 | 2,675,314.00 | 2,851,757.00 |
| 递延收入流动(元) | 174,897.00 | 27,779.00 | 27,779.00 | 27,779.00 | 100,000.00 | 100,000.00 |
| 流动负债其他项目(元) | 1,108,436.00 | 1,059,852.00 | 1,577,979.00 | 1,838,055.00 | 2,432,282.00 | 5,739,903.00 |
| 流动负债合计(元) | 15,007,226.00 | 12,948,525.00 | 11,395,866.00 | 8,874,119.00 | 9,724,318.00 | 13,583,122.00 |
| 非流动负债： | ||||||
| 融资租赁负债非流动(元) | - | - | - | 63,209.00 | - | - |
| 衍生工具负债非流动(元) | 1,072,893.00 | 5,480,646.00 | 7,492.00 | 12,037.00 | 70,728.00 | 90,268.00 |
| 递延收入非流动(元) | 164,357.00 | 171,302.00 | 178,247.00 | 185,191.00 | 700,000.00 | 725,000.00 |
| 非流动负债其他项目(元) | - | - | - | - | 157,246.00 | 250,361.00 |
| 非流动负债合计(元) | 1,237,250.00 | 5,651,948.00 | 185,739.00 | 260,437.00 | 927,974.00 | 1,065,629.00 |
| 总负债(元) | 16,244,476.00 | 18,600,473.00 | 11,581,605.00 | 9,134,556.00 | 10,652,292.00 | 14,648,751.00 |
| 股东权益： | ||||||
| 普通股(元) | 15,831.00 | 15,051.00 | 15,051.00 | 15,051.00 | 15,051.00 | 15,026.00 |
| 优先股(元) | 330,000.00 | 157,303.00 | 157,303.00 | 157,303.00 | - | - |
| 库存股(元) | -5,250.00 | -5,250.00 | -5,250.00 | -5,250.00 | -5,250.00 | -5,250.00 |
| 股本溢价(元) | 310,245,208.00 | 303,815,511.00 | 303,746,217.00 | 304,072,176.00 | 303,869,991.00 | 304,330,933.00 |
| 留存收益(元) | -322,081,115.00 | -313,506,993.00 | -304,564,086.00 | -301,236,550.00 | -296,837,649.00 | -288,440,428.00 |
| 归属于母公司股东权益(元) | -11,495,326.00 | -9,524,378.00 | -650,765.00 | 3,002,730.00 | 7,042,143.00 | 15,900,281.00 |
| 股东权益合计(元) | -11,495,326.00 | -9,524,378.00 | -650,765.00 | 3,002,730.00 | 7,042,143.00 | 15,900,281.00 |
| 负债及股东权益合计(元) | 4,749,150.00 | 9,076,095.00 | 10,930,840.00 | 12,137,286.00 | 17,694,435.00 | 30,549,032.00 |
| 公告日期 | 2023-08-21 | 2023-05-15 | 2023-03-16 | 2022-11-14 | 2022-08-10 | 2022-05-16 |
| 会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 | 美国会计准则 |
| 审计意见 | ||||||
| 核数师 |